Hoch M - Search Results

1

Absolute Bioavailability of Ponesimod, a Selective S1P₁ Receptor Modulator, in Healthy Male Subjects.

Boehler M, Juif PE, Hoch M, Dingemanse J. Boehler M, et al. Among authors: hoch m. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):129-134. doi: 10.1007/s13318-016-0325-6. Eur J Drug Metab Pharmacokinet. 2017. PMID: 26883438 Clinical Trial.

2

Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects.

Hoch M, Hoever P, Haschke M, Krähenbühl S, Dingemanse J. Hoch M, et al. J Clin Pharmacol. 2011 Jul;51(7):1116-21. doi: 10.1177/0091270010377634. Epub 2010 Sep 17. J Clin Pharmacol. 2011. PMID: 20852003 Clinical Trial. No abstract available.

3

Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.

Hoch M, Hoever P, Alessi F, Marjason J, Dingemanse J. Hoch M, et al. Pharmacology. 2011;88(3-4):121-6. doi: 10.1159/000330098. Epub 2011 Aug 25. Pharmacology. 2011. PMID: 21865769 Clinical Trial.

4

Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.

Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Hoch M, et al. Pharmacology. 2012;89(1-2):53-7. doi: 10.1159/000335367. Epub 2012 Feb 1. Pharmacology. 2012. PMID: 22302127 Clinical Trial.

5

Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J. Hoch M, et al. Eur Neuropsychopharmacol. 2013 Feb;23(2):107-17. doi: 10.1016/j.euroneuro.2012.04.012. Epub 2012 May 30. Eur Neuropsychopharmacol. 2013. PMID: 22658401 Clinical Trial.

6

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.

Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J. Hoch M, et al. Eur J Clin Pharmacol. 2013 Mar;69(3):523-32. doi: 10.1007/s00228-012-1403-6. Epub 2012 Sep 19. Eur J Clin Pharmacol. 2013. PMID: 22990330 Clinical Trial.

7

Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.

Hoch M, Hoever P, Theodor R, Dingemanse J. Hoch M, et al. Eur J Clin Pharmacol. 2013 Jun;69(6):1235-45. doi: 10.1007/s00228-012-1470-8. Epub 2013 Jan 20. Eur J Clin Pharmacol. 2013. PMID: 23334403 Clinical Trial.

8

Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.

Dingemanse J, Hoever P, Hoch M, Treiber A, Wagner-Redeker W, Miraval T, Hopfgartner G, Shakeri-Nejad K. Dingemanse J, et al. Among authors: hoch m. Drug Metab Dispos. 2013 May;41(5):1046-59. doi: 10.1124/dmd.112.050120. Epub 2013 Feb 21. Drug Metab Dispos. 2013. PMID: 23431113

9

Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.

Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J. Shakeri-Nejad K, et al. Among authors: hoch m. Eur J Pharm Sci. 2013 Aug 16;49(5):836-44. doi: 10.1016/j.ejps.2013.06.002. Epub 2013 Jun 11. Eur J Pharm Sci. 2013. PMID: 23770377 Clinical Trial.

10

Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans.

Hoch M, Wank J, Kluge I, Wagner-Redeker W, Dingemanse J. Hoch M, et al. Drugs R D. 2013 Dec;13(4):253-69. doi: 10.1007/s40268-013-0031-7. Drugs R D. 2013. PMID: 24214422 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

432 results

Search Page

Filters